Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
CX3CL1/fractalkine is a chemokine with a unique CX3C motif. Fractalkine is synthesized in endothelial cells as a membrane protein, and the N-terminal domain containing a CX3C motif is cleaved and secreted. Fractalkine is the first described cell-surface anchored chemokine and has potent mononuclear cell-directed adhesion and chemotactic properties. Fractalkine is involved in the pathogenesis of various chronic inflammatory diseases, such as rheumatoid arthritis and atherosclerosis.
CX3CL1/Fractalkine in Human Breast Cancer Tissue. CX3CL1/Fractalkine was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using 15 ug/ml Human CX3CL1/Fractalkine Chemokine Domain Antigen Affinity-purified Polyclonal Antibody overnight at 4°C. Tissue was stained (red) and counterstained with hematoxylin (blue).
Chemotaxis Induced by CX3CL1/Fractalkine and Neutralization by Human CX3CL1/Fractalkine Antibody. Recombinant Human CX3CL1/Fractalkine chemoattracts the BaF3 mouse pro-B cell line transfected with human CX3CR1 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin. Chemotaxis elicited by Recombinant Human CX3CL1/Fractalkine (20 ng/ml) is neutralized (green line) by increasing concentrations of Human CX3CL1/Fractalkine Chemokine Domain Antigen Affinity-purified Polyclonal Antibody. The ND50 is typically 0.3-1.5 ug/ml.
Requested From: United States
Date Requested: 2/22/2017